ASCO 2022

What are the cosenquences of the new OS data for CDK4/6…

More data needed: Are the results clinical meaningful?…

Paradigm shift in breast cancer: Where do we use the…

Transatlantic differences in ADC side effects…

Patients perspectives: ADCs - how do manage the new,…

How to determine progress of disease? How to proceed…

ADCs & CDK4/6i - paradigm shifts and therapy switches…

Determining HER2 receptor expression: How do we target…

Improvment of PFS & OS with activated alteration…

Benefit of CDK4/6 Switch after Progression

Discontiunation of trial is disappointing despite…

Palbociclib - Overall survival data

No effect for local treatment of metastasis

Impressive and practice changing data of ADCs mark the…

Gamechanger in breast cancer

Possible explanations of the negative study

Good therapeutic option in HR+ HER2- mBC after failure…

Practice changing data

New standard of care for HR+/Her2low patients

Combi SERD + Palbo reduces proliferation better than…

Exciting advances across a wide subset of breast…

First evidence on benefit of CDK4/6 inhibitors beyond…

Breakthrough news with antibody drug conjugate

Fascinating data of ADCs in breast cancer at ASCO22

No changes in clinical practice after new CDK4/6i-data

Exciting and practice changing news for HR+/Her2low MBC…

Revolution in the field of HR+ disease

New agents for the clincial practice

Smart chemotherapy improves PFS

Oligometastasis: no advantage of additional…

Disappoiting final OS data and its implications for our…

SG may be a good option for pre-treated HR+/Her2- pts

Option for overcoming endocrine resistance?

Combination of ctDNA and TKa assesment may improve…

New SoC for large subpopulation of breast cancer…

ADC: future therapeutic option in advanced HR+/HER2 BC

T-DxD should be the new SoC for Her2low MBC patients

Additional administration of ribociclib improves PFS…

SG is a new therapy option for HR+/HER2- MBC patients

Endocrine therapy alone is important in treatment of…

Patritumab Deruxtecan: HER3-targeted ADC in HER3…

My ASCO22 highlights in metastatic breast cancer

SG come nuova opzione di cura per le pazienti con…

I nuovi impressionanti risultati degli ADC a l’ASCO…

Noutăți inovatoare cu conjugatul de medicamente cu…

Novità entusiasmanti e practice changing per le…

Nowy standard dla znaczącej subopulacji chorych na raka…

Il sacituzumab govitecan migliora il PFS nei tumori…

La valutazione combinata di ctDNA e TKa può aiutare a…

Les nouvelles données impressionnantes des ADC à l’ASCO…

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

Una rivoluzione per il tumore mammario…

Adding towards deescalation in luminal A EBC by…

Neoadjuvant Pembro decreased RCB. SG - first promising…

Long term overall survival benefit of Denosumab in…

CT benefit for elderly patients, if they are able to…

My ASCO22 highlights in early breast cancer

High concordance of local, central IHC and RT-PCR for…

Immunotherapy - Part 1

Molecular landscape - Part 2

Immunotherapy - Part 2

New treatment options for METexon 14 skipping:…

CLN-081 is a promising new agent for EGFR exon 20…

COSMIC-021: Not practice-changing, but interesting…

Options after progression to chemo/IO and for KRASG12C…

Role of IO and chemo-IO in patients with PD-L1 > 50%

PD-L1 over 50%: Chemo-IO or IO?

New option in patients harboring METex14 mutation

Promising results for pre-treated patients with…

CLN-081 for patients with metastatic NSCLC and an…

Bispecific Antibodies - the cMET field is moving

In the second line: Options for Immunotherapy…

Is adagrasib an alternative to sotorasib?

Amivantamab as a future option for METex14 patients?

Strategies for PD-L1 > 50%

KRASG12C mutation: Adagrasib is comparabale to…

Multiple aquired resistance mutations may drive disease…

A chemo-free option in patients with EGFR-mutation

Veelbelovende resultaten voor voorbehandelde patienten…

Nuevas terapias para el CPCNP avanzado

COSMIC-021: Nicht praxisverändernd, aber interessante…

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…

Nieuwe behandelopties voor METexon 14 skipping:…

Was tun nach Versagen einer Chemoimmun-Therapie?

L’adagrasib, inhibiteur de la mutation KRASG12C: une…

Une nouvelle option, l’amivantamab, en situation de…

CLN-081 voor patienten met gemetastaseerd NSCLC en een…

Segunda Linea: opciones tras resistencia a…

Bispezifische Antikörper - Neues von CHRYSALIS

Neoadjuvant and adjuvant therapy - Part 2

Perspectives on multimodality

A new option in neoadjuvant chemoimmunotherapy

NADIM-II strengthens the findings from CheckMate-816

New treatment approaches in Stage III

Neue Ansätze im Stadium III

No benefit for tiragolumab / novel anti-PD-1 mAB…

SKYSCRAPER-02: Subgroups could be important

Immuncheckpoint-inhibitor therapy

mCRPC: LuPSMA - new treatment option in mCRPC

PARP inhibitors in mCRPC: Do we need more genetic…

3 year overall survival of TheraP study

SUV mean at PET images as a prognostic tool for PSMA…

TheraP shows no difference in overall survival between…

LuPSMA & cabazitaxel are better than SoC alone

Surrogate endpoints in mHSPC

The efficacy of doublets in mHSPC

SUVmean is highly predictive of better PFS and OS

Value of triple-therapy - complimentary study to…

PFS good surrogate endpoint for overall survival

Ongoing trial invetiagting the impact of…

Lu-PSMA in the third line

Lu-PSMA effective regardless of prior or concomitant…

Frequent imaging for early detection of metastases in…

The highlights in GU cancers of ASCO22

Further updates from the VISION trial

No big scoop, but encouraging results

ADT alone is no longer standard of care

SHR3680 - do we need a new androgen receptor inhibitor

GGT impacts PCa patients care

Arbiraterone + Olaparib: Is it synergistic?

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas…

Lo mas destacado en tumores GU en ASCO 2022

Kvantifiering av PMSA PET upptaget som prognostisk…

Pas de nouvelles sensationnelles mais des données…

Treårs överlevnadsresultat i TheraP studien.

EVEREST: Inisghts from the negative trial

The relevance of quality of life in kidney cancer!

What are the consequences for future trial design?

Should Everolimus be revisited for high-risk patients?

Depth of remission in firstline

QoL & DepOR correlate with clinical outcomes - reminder…

Belzutifann shows good tumor activity in renal cancer

Combi Axi + Pembro also successful with good risk…

The highlights in GU cancers of ASCO22

Importance of health related quality of life

PSMA-PET may improve imaging of clear cell RCC

Should we be looking at Everolimus in the future?

Lo mas destacado en tumores GU en ASCO 2022

ADCs: do we enter a new era of therapy for urothelial…

New data on TKi utilization in bladder cancer

Investigating sasanlimab in BCG-unresponsive NMIBC

BCG failure

ADCs: News from ASCO 2022

The highlights in GU cancers of ASCO22

Exciting future for ADCs

My highlights in localized urothelial cancer

Perioperative immuno-chemotherapy in MIBC

My highlights of metastasized urothelial cancer

No big scoop, but encouraging results

The end of of VEGF-targeted therapy in urothelial…

Lo mas destacado en tumores GU en ASCO 2022

Opportunities & challenges of cancer genetics

Radiotherapy as a new standard for cisplatin ineligible…

Few testicular tumors after 5 years

Systemic therapy

Precision oncology - NTRK worth to search the patients